Prognostic factors of pazopanib in advanced soft tissue sarcomas


A new analysis confirmed the importance of known prognostic factors such as performance status and tumor grading for having a long-term outcome in patients treated with pazopanib for metastatic soft tissue sarcoma. In addition, hemoglobin at baseline was found to be a new prognostic factor.

Pazopanib tolerated best in kidney cancer study


A trial comparing pazopanib and sunitinib found pazopanib to have better safety and health-related quality-of-life profiles among persons with metastatic renal cell carcinoma.

ASCO: Pazopanib linked to greater advanced ovarian cancer survival

ASCO: Pazopanib linked to greater advanced ovarian cancer survival

Maintenance therapy with pazopanib is linked to longer progression-free survival after surgery for advanced disease.

Annual report highlights 2012 cancer advances

The American Society of Clinical Oncology has released a nearly 100-page report detailing the year's most significant developments in cancer.

How kidney cancer therapies could improve quality of life

Kidney cancer drugs in development could improve patients' quality of life and allow more effective treatment, according to Professor Robert Hawkins of Manchester University.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs